New hope for lung cancer patients: experimental drug SYS6010 faces off against chemotherapy

NCT ID NCT07442565

Not yet recruiting Disease control Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial compares an experimental drug called SYS6010 with the standard chemotherapy docetaxel in about 506 people with advanced non-squamous non-small cell lung cancer that has not responded to prior treatments. The study aims to see if SYS6010 can slow cancer growth or improve survival better than docetaxel. Participants will be randomly assigned to receive either SYS6010 or docetaxel, and their health will be monitored over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6010 (an experimental drug) compared to docetaxel (a standard chemotherapy)
What this could lead to: If SYS6010 works better than docetaxel, it could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The experimental drug may not be more effective or could have unexpected side effects compared to the standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.